BiotechTube

A2B694 + A2B543

Phase 1/2Recruiting
1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Solid Tumor, Adult

Conditions

Solid Tumor, Adult, Colorectal Cancer, NSCLC, Non Small Cell Lung Cancer, NSCLC, Recurrent, Non-Small Cell Squamous Lung Cancer, Pancreas Cancer, Pancreatic Neoplasm, Colorectal Adenocarcinoma, CRC, Colon Cancer, Rectal Cancer, Cancer, Ovarian Cancer, Ovarian Neoplasms, Mesothelioma, Mesothelioma, Malignant, Ovary Cancer, Lung Cancer, MESOM

Trial Timeline

Apr 3, 2024 → Jun 1, 2029

NCT ID
NCT06051695

About A2B694 + A2B543

A2B694 + A2B543 is a phase 1/2 stage product being developed by Tempus AI for Solid Tumor, Adult. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06051695. Target conditions include Solid Tumor, Adult, Colorectal Cancer, NSCLC.

What happened to similar drugs?

5 of 13 similar drugs in Solid Tumor, Adult were approved

Approved (5) Terminated (2) Active (8)
✅DurvalumabAstraZenecaApproved
✅ARM A : IV iron + epoietin zeta + ARM B: IV iron + epoietin zeta sequence + ARM C : single epoietin zetaRocheApproved
✅denosumab + pamidronateAmgenApproved
✅Sacituzumab Govitecan-hiyGilead SciencesApproved
✅Binimetinib only treatment + Encorafenib only Treatment + Encorafenib & Binimetinib Treatment + Treatment of Encorafenib & Binimetinib & Ribociclib + Treatment of Encorafenib & Binimetinib & CetuximabPfizerApproved
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
🔄MEDI4736 (Durvalumab) + MEDI4736 (Durvalumab) + TremelimumabAstraZenecaPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06051695Phase 1/2Recruiting

Competing Products

20 competing products in Solid Tumor, Adult

See all competitors
ProductCompanyStageHype Score
ALG.APV-527Alligator Bioscience ABPhase 1/2
18
ATOR-1017Alligator Bioscience ABPhase 1
19
ATOR-1015Alligator Bioscience ABPhase 1
19
mRNA-4359ModernaPhase 2
0
mRNA-2752 + DurvalumabAstraZenecaPhase 1
29
mRNA-4106ModernaPhase 1
0
mRNA-4157 + Pembrolizumab + SoC TreatmentMerckPhase 1
33
mRNA-2416ModernaPhase 2
0
E7050EisaiPhase 1
29
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
14
EXS21546BiotrialPhase 1/2
14
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
11
BBP-398 + sotorasibBridgeBio PharmaPhase 1
18
BBP-398 (Formerly known as IACS-15509)BridgeBio PharmaPhase 1
18
SON-1010Sonnet BioTherapeuticsPhase 1
27
SON-1010Sonnet BioTherapeuticsPhase 1/2
18
RC220 + Doxorubicin (Adriamycin)Race OncologyPhase 1
30
BT1718Bicycle TherapeuticsPhase 1/2
22
NL-201 + Pembrolizumab Injection [Keytruda]NeurogenePhase 1
19
ZN-c3 + Carboplatin + Pegylated liposomal doxorubicin + Paclitaxel + Gemcitabine + BevacizumabZentalis PharmaceuticalsPhase 1
26